Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10060733HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060734HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS30079529HIVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS20053630HPVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS20045816HPVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS44021205HTLV-1ENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS44034752HTLV-1ENSG00000118271.12protein_codingTTRNoNo7276P02766
TCGA Plot Options
Drug Information
GeneTTR
DrugBank IDDB16309
Drug NameRevusiran
Target IDBE0000337
UniProt IDP02766
Regulation Typeregulator
PubMed IDs32062791
CitationsJudge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, Gillmore J, Garg P, Vaishnaw AK, Harrop J, Powell C, Karsten V, Zhang X, Sweetser MT, Vest J, Hawkins PN: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 Jun;34(3):357-370. doi: 10.1007/s10557-019-06919-4.
GroupsInvestigational
Direct Classification
SMILES
Pathways
PharmGKB
ChEMBL